Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/5/2020
SIETES contiene 93011 citas

 
 
 1 a 20 de 1769 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020:22 de mayo. [Ref.ID 103632]
2. Cita con resumen
Zhu H, Bateman BT, Gray KJ, Hernandez-Diaz S, Mogun H, Starub L, Huybrechts KF. Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. BMJ 2020;369:20 de mayo. [Ref.ID 103628]
3. Cita con resumen
Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Ueda P. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ 2020;369:29 de abril. [Ref.ID 103626]
6. Cita con resumen
Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, Aizer A, Holmes D, Bernstein S, Spinelli M, Park DS, Chinitz LA, Jankelson L. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med 2020:24 de abril. [Ref.ID 103600]
7.Enlace a cita original Cita con resumen
Suissa S, Dell'Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD. Cohort study in real-world clinical practice. Chest 2020;157:abril. [Ref.ID 103589]
8. Cita con resumen
Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, Wilson LE, Holzbauer SM, Phipps EC, Dumyati GK, Beldavs ZG, Kainer MA, et al.. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med 2020;382:2 de abril. [Ref.ID 103578]
9. Cita con resumen
Jefferson T, Demasi M, Doshi P. Statins for primary prevention: what is the regulator’s role?. BMJ Evidence-Based Medicine 2020:marzo. [Ref.ID 103575]
10. Cita con resumen
Simon TG, Duberg A-S, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med 2020;382:12 de marzo. [Ref.ID 103565]
12. Cita con resumen
14. Cita con resumen
Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. Tolerability of antiseizure medications in individuals with newly diagnosed epilepsy. JAMA Neurology 2020:1. [Ref.ID 103540]
15. Cita con resumen
Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf 2020;43:febrero. [Ref.ID 103539]
16. Cita con resumen
Colloca L, Barsky AJ. Placebo and nocebo effects. N Engl J Med 2020;382:6 de febrero. [Ref.ID 103518]
17.Enlace a cita original Cita con resumen
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ 2020;368:5 de febrero. [Ref.ID 103514]
18. Cita con resumen
McEvoy JB, Daya N, Rahman F, Hoogeveen RC, Blumenthal RS, Shah AM, Ballantyne CM, Coresh J, Selvin E. Association of isolated diastolic hypertension as defined by the 2017 ACC/AHA blood pressure guideline with incident cardiovascular outcomes. JAMA 2020;323:28 de enero. [Ref.ID 103512]
19. Cita con resumen
Pasternak B, Ueda P, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveern K, Jonasson C, Wintzell V, Melbye M, Svanström H. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ 2019;366:29 de agosto. [Ref.ID 103243]
20. Cita con resumen
Garcia P, Lafaurie M. Le priapisme, un effet indésirable des neuroleptiques à ne pas méconnaître. BIP Occitanie 2019;26:76. [Ref.ID 103241]
Seleccionar todas
 
 1 a 20 de 1769 siguiente >>